Search

Your search keyword '"Barba, Maddalena"' showing total 595 results
Start Over Author "Barba, Maddalena"
595 results on '"Barba, Maddalena"'

51. Surgical Site Infections in Breast Cancer Patients Undergoing Surgery During the Covid-19 Pandemic. Preliminary Data from an Italian Oncologic Hub.

Author

Cappelli, Sonia, primary, Pelle, Fabio, additional, Clementi, Marco, additional, Barba, Maddalena, additional, Vici, Patrizia, additional, Capomolla, Elisabetta, additional, Pizzuti, Laura, additional, Corallino, Diletta, additional, Sperduti, Isabella, additional, Graziano, Franco, additional, Piarulli, Loredana, additional, Cavicchi, Flavia, additional, Magagnano, Domenico, additional, De vita, Roy, additional, Quercia, Vittorio, additional, Pozzi, Marcello, additional, Costantini, Maurizio, additional, Ciliberto, Gennaro, additional, and Botti, Claudio, additional

Published
2021
Full Text
View/download PDF

52. Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives

Author

Krasniqi, Eriseld, primary, Barba, Maddalena, additional, Venuti, Aldo, additional, Pizzuti, Laura, additional, Cappuzzo, Federico, additional, Landi, Lorenza, additional, Carpano, Silvia, additional, Marchetti, Paolo, additional, Villa, Alice, additional, Vizza, Enrico, additional, Giuliano, Greta, additional, Mazzotta, Marco, additional, Marinelli, Daniele, additional, Gnignera, Sandra, additional, Vincenzoni, Cristina, additional, Stranges, Vincenzo, additional, Sergi, Domenico, additional, Giordano, Antonio, additional, Tomao, Federica, additional, Maugeri-Saccà, Marcello, additional, Sanguineti, Giuseppe, additional, Di Lisa, Francesca Sofia, additional, Tomao, Silverio, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2021
Full Text
View/download PDF

53. Additional file 1 of Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Author

Bon, Giulia, Pizzuti, Laura, Laquintana, Valentina, Loria, Rossella, Porru, Manuela, Marchiò, Caterina, Krasniqi, Eriseld, Barba, Maddalena, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, Verde, Nicla La, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Barchiesi, Giacomo, Mazzotta, Marco, Marinelli, Daniele, Tomao, Silverio, Marchetti, Paolo, Valerio, Maria Rosaria, Mirabelli, Rosanna, Russo, Antonio, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Giotta, Francesco, Garufi, Carlo, Cazzaniga, Marina, Medico, Pietro Del, Roselli, Mario, Sanguineti, Giuseppe, Sperduti, Isabella, Sapino, Anna, Maria, Ruggero De, Leonetti, Carlo, Leo, Angelo Di, Ciliberto, Gennaro, Falcioni, Rita, and Vici, Patrizia

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2020
Full Text
View/download PDF

54. Additional file 2 of Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Author

Bon, Giulia, Pizzuti, Laura, Laquintana, Valentina, Loria, Rossella, Porru, Manuela, Marchiò, Caterina, Krasniqi, Eriseld, Barba, Maddalena, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, Verde, Nicla La, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Barchiesi, Giacomo, Mazzotta, Marco, Marinelli, Daniele, Tomao, Silverio, Marchetti, Paolo, Valerio, Maria Rosaria, Mirabelli, Rosanna, Russo, Antonio, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Giotta, Francesco, Garufi, Carlo, Cazzaniga, Marina, Medico, Pietro Del, Roselli, Mario, Sanguineti, Giuseppe, Sperduti, Isabella, Sapino, Anna, Maria, Ruggero De, Leonetti, Carlo, Leo, Angelo Di, Ciliberto, Gennaro, Falcioni, Rita, and Vici, Patrizia

Subjects
Data_FILES
Abstract

Additional file 2.

Published
2020
Full Text
View/download PDF

55. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

Author

Krasniqi, E, Pizzuti, L, Barchiesi, G, Sergi, D, Carpano, S, Botti, C, Kayal, R, Sanguineti, G, Marchetti, P, Botticelli, A, Marinelli, D, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Tomao, S, Tonini, G, Santini, D, Michelotti, A, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Cazzaniga, M, Moscetti, L, Fabbri, A, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Garufi, C, Di Stefano, P, Mirabelli, R, Veltri, E, Paris, I, Giotta, F, Lorusso, V, Landucci, E, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Valerio, M, Berardi, R, Pistelli, M, Cannita, K, Zamagni, C, Garrone, O, Baldini, E, Livi, L, Meattini, I, Del Medico, P, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Villa, A, Sperduti, I, Mazzotta, M, Barba, M, Giordano, A, Vici, P, Krasniqi, Eriseld, Pizzuti, Laura, Barchiesi, Giacomo, Sergi, Domenico, Carpano, Silvia, Botti, Claudio, Kayal, Ramy, Sanguineti, Giuseppe, Marchetti, Paolo, Botticelli, Andrea, Marinelli, Daniele, Gamucci, Teresa, Natoli, Clara, Grassadonia, Antonino, Tinari, Nicola, Tomao, Silverio, Tonini, Giuseppe, Santini, Daniele, Michelotti, Aandrea, Mentuccia, Lucia, Vaccaro, Aangela, Magnolfi, Emanuela, Gelibter, Alain, Magri, Valentina, Cortesi, Enrico, D'Onofrio, Loretta, Cassano, Alessandra, Cazzaniga, Marina, Moscetti, Luca, Fabbri, Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Bria, Emilio, La Verde, Nicla, Garufi, Carlo, Di Stefano, Pia, Mirabelli, Rossana, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Lorusso, Vito, Landucci, Elisa, Ficorella, Corrado, Roselli, Mario, Adamo, Vincenzo, Ricciardi, Giuseppina, Russo, Antonio, Valerio, Maria Rosaria, Berardi, Rossana, Pistelli, Mirco, Cannita, Katia, Zamagni, Claudio, Garrone, Ornella, Baldini, Editta, Livi, Lorenzo, Meattini, Icro, Del Medico, Pietro, Generali, Daniele, De Maria, Ruggero, Risi, Emanuela, Ciliberto, Gennaro, Villa, Alice, Sperduti, Isabella, Mazzotta, Marco, Barba, Maddalena, Giordano, Antonio, Vici, Patrizia, Krasniqi, E, Pizzuti, L, Barchiesi, G, Sergi, D, Carpano, S, Botti, C, Kayal, R, Sanguineti, G, Marchetti, P, Botticelli, A, Marinelli, D, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Tomao, S, Tonini, G, Santini, D, Michelotti, A, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Cazzaniga, M, Moscetti, L, Fabbri, A, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Garufi, C, Di Stefano, P, Mirabelli, R, Veltri, E, Paris, I, Giotta, F, Lorusso, V, Landucci, E, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Valerio, M, Berardi, R, Pistelli, M, Cannita, K, Zamagni, C, Garrone, O, Baldini, E, Livi, L, Meattini, I, Del Medico, P, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Villa, A, Sperduti, I, Mazzotta, M, Barba, M, Giordano, A, Vici, P, Krasniqi, Eriseld, Pizzuti, Laura, Barchiesi, Giacomo, Sergi, Domenico, Carpano, Silvia, Botti, Claudio, Kayal, Ramy, Sanguineti, Giuseppe, Marchetti, Paolo, Botticelli, Andrea, Marinelli, Daniele, Gamucci, Teresa, Natoli, Clara, Grassadonia, Antonino, Tinari, Nicola, Tomao, Silverio, Tonini, Giuseppe, Santini, Daniele, Michelotti, Aandrea, Mentuccia, Lucia, Vaccaro, Aangela, Magnolfi, Emanuela, Gelibter, Alain, Magri, Valentina, Cortesi, Enrico, D'Onofrio, Loretta, Cassano, Alessandra, Cazzaniga, Marina, Moscetti, Luca, Fabbri, Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Bria, Emilio, La Verde, Nicla, Garufi, Carlo, Di Stefano, Pia, Mirabelli, Rossana, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Lorusso, Vito, Landucci, Elisa, Ficorella, Corrado, Roselli, Mario, Adamo, Vincenzo, Ricciardi, Giuseppina, Russo, Antonio, Valerio, Maria Rosaria, Berardi, Rossana, Pistelli, Mirco, Cannita, Katia, Zamagni, Claudio, Garrone, Ornella, Baldini, Editta, Livi, Lorenzo, Meattini, Icro, Del Medico, Pietro, Generali, Daniele, De Maria, Ruggero, Risi, Emanuela, Ciliberto, Gennaro, Villa, Alice, Sperduti, Isabella, Mazzotta, Marco, Barba, Maddalena, Giordano, Antonio, and Vici, Patrizia

Abstract

Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p =.15), while BMI ≥ 30 was associated with worse OS (p =.003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p =.001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p =.03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T-DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.

Published
2020

56. COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience

Author

Barba, Maddalena, primary, Krasniqi, Eriseld, additional, Pizzuti, Laura, additional, Mazzotta, Marco, additional, Marinelli, Daniele, additional, Giuliano, Greta, additional, Di Liso, Francesca Sofia, additional, Cappuzzo, Federico, additional, Landi, Lorenza, additional, Tomao, Silverio, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2021
Full Text
View/download PDF

58. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Author

Pizzuti, Laura, primary, Krasniqi, Eriseld, additional, Sperduti, Isabella, additional, Barba, Maddalena, additional, Gamucci, Teresa, additional, Mauri, Maria, additional, Veltri, Enzo Maria, additional, Meattini, Icro, additional, Berardi, Rossana, additional, Di Lisa, Francesca Sofia, additional, Natoli, Clara, additional, Pistelli, Mirco, additional, Iezzi, Laura, additional, Risi, Emanuela, additional, D’Ostilio, Nicola, additional, Tomao, Silverio, additional, Ficorella, Corrado, additional, Cannita, Katia, additional, Riccardi, Ferdinando, additional, Cassano, Alessandra, additional, Bria, Emilio, additional, Fabbri, Maria Agnese, additional, Mazzotta, Marco, additional, Barchiesi, Giacomo, additional, Botticelli, Andrea, additional, D’Auria, Giuliana, additional, Ceribelli, Anna, additional, Michelotti, Andrea, additional, Russo, Antonio, additional, Salimbeni, Beatrice Taurelli, additional, Sarobba, Giuseppina, additional, Giotta, Francesco, additional, Paris, Ida, additional, Saltarelli, Rosa, additional, Marinelli, Daniele, additional, Corsi, Domenico, additional, Capomolla, Elisabetta Maria, additional, Sini, Valentina, additional, Moscetti, Luca, additional, Mentuccia, Lucia, additional, Tonini, Giuseppe, additional, Raffaele, Mimma, additional, Marchetti, Luca, additional, Minelli, Mauro, additional, Ruggeri, Enzo Maria, additional, Scavina, Paola, additional, Bacciu, Olivia, additional, Salesi, Nello, additional, Livi, Lorenzo, additional, Tinari, Nicola, additional, Grassadonia, Antonino, additional, Fedele Scinto, Angelo, additional, Rossi, Rosalinda, additional, Valerio, Maria Rosaria, additional, Landucci, Elisabetta, additional, Stani, Simonetta, additional, Fratini, Beatrice, additional, Maugeri-Saccà, Marcello, additional, De Tursi, Michele, additional, Maione, Angela, additional, Santini, Daniele, additional, Orlandi, Armando, additional, Lorusso, Vito, additional, Cortesi, Enrico, additional, Sanguineti, Giuseppe, additional, Pinnarò, Paola, additional, Cappuzzo, Federico, additional, Landi, Lorenza, additional, Botti, Claudio, additional, Tomao, Federica, additional, Cappelli, Sonia, additional, Bon, Giulia, additional, Pelle, Fabio, additional, Cavicchi, Flavia, additional, Fiorio, Elena, additional, Foglietta, Jennifer, additional, Scagnoli, Simone, additional, Marchetti, Paolo, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2021
Full Text
View/download PDF

59. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

Author

Krasniqi, Eriseld, primary, Pizzuti, Laura, additional, Valerio, Maria Rosaria, additional, Capomolla, Elisabetta, additional, Botti, Claudio, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Anselmi, Elisabetta, additional, Tomao, Silverio, additional, Giordano, Antonio, additional, Ficorella, Corrado, additional, Cannita, Katia, additional, Livi, Lorenzo, additional, Meattini, Icro, additional, Mauri, Maria, additional, Greco, Filippo, additional, Veltri, Enzo Maria, additional, Michelotti, Andrea, additional, Moscetti, Luca, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Paris, Ida, additional, Tomao, Federica, additional, Santini, Daniele, additional, Tonini, Giuseppe, additional, Villa, Alice, additional, Gebbia, Vittorio, additional, Gamucci, Teresa, additional, Ciliberto, Gennaro, additional, Sperduti, Isabella, additional, Mazzotta, Marco, additional, Barba, Maddalena, additional, and Vici, Patrizia, additional

Published
2021
Full Text
View/download PDF

61. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade. The SePHER Study.

Author

Bon, Giulia, primary, Pizzuti, Laura, additional, Laquintana, Valentina, additional, Loria, Rossella, additional, Porru, Manuela, additional, Marchiò, Caterina, additional, Krasniqi, Erisled, additional, Barba, Maddalena, additional, Maugeri-Saccà, Marcello, additional, Gamucci, Teresa, additional, Berardi, Rossana, additional, Livi, Lorenzo, additional, Ficorella, Corrado, additional, Natoli, Clara, additional, Cortesi, Enrico, additional, Generali, Daniele, additional, Verde, Nicla La, additional, Cassano, Alessandra, additional, Bria, Emilio, additional, Moscetti, Luca, additional, Michelotti, Andrea, additional, Adamo, Vincenzo, additional, Zamagni, Claudio, additional, Tonini, Giuseppe, additional, Barchiesi, Giacomo, additional, Mazzotta, Marco, additional, Marinelli, Daniele, additional, Tomao, Silverio, additional, Marchetti, Paolo, additional, Valerio, Maria Rosaria, additional, Mirabelli, Rosanna, additional, Russo, Antonio, additional, Fabbri, Maria Agnese, additional, D'Ostilio, Nicola, additional, Veltri, Enzo, additional, Corsi, Domenico, additional, Garrone, Ornella, additional, Paris, Ida, additional, Sarobba, Giuseppina, additional, Giotta, Francesco, additional, Garufi, Carlo, additional, Cazzaniga, Marina, additional, Medico, Pietro Del, additional, Roselli, Mario, additional, Sanguineti, Giuseppe, additional, Sperduti, Isabella, additional, Sapino, Anna, additional, De Maria, Ruggero, additional, Leonetti, Carlo, additional, Leo, Angelo Di, additional, Ciliberto, Gennaro, additional, Falcioni, Rita, additional, and Vici, Patrizia, additional

Published
2020
Full Text
View/download PDF

62. Multicohort and cross‐platform validation of a prognostic Wnt signature in colorectal cancer

Author

Goeman, Frauke, primary, De Nicola, Francesca, additional, Amoreo, Carla Azzurra, additional, Scalera, Stefano, additional, Marinelli, Daniele, additional, Sperati, Francesca, additional, Mazzotta, Marco, additional, Terrenato, Irene, additional, Pallocca, Matteo, additional, Ciuffreda, Ludovica, additional, Sperandio, Eleonora, additional, Barba, Maddalena, additional, Pizzuti, Laura, additional, Sergi, Domenico, additional, Amodio, Antonella, additional, Paoletti, Giancarlo, additional, Krasniqi, Eriseld, additional, Vici, Patrizia, additional, Casini, Beatrice, additional, Gallo, Enzo, additional, Buglioni, Simonetta, additional, Diodoro, Maria Grazia, additional, Pescarmona, Edoardo, additional, Vitale, Ilio, additional, De Maria, Ruggero, additional, Grazi, Gian Luca, additional, Ciliberto, Gennaro, additional, Fanciulli, Maurizio, additional, and Maugeri‐Saccà, Marcello, additional

Published
2020
Full Text
View/download PDF

63. HER2 Nuclear Translocation and Decreased T-DM1 Efficacy in HER2 Positive Advanced Breast Cancer Treated with Dual HER2 Blockade. The SePHER Study.

Author

Bon, Giulia, primary, Pizzuti, Laura, additional, Laquintana, Valentina, additional, Loria, Rossella, additional, Porru, Manuela, additional, Marchiò, Caterina, additional, Krasniqi, Erisled, additional, Barba, Maddalena, additional, Maugeri-Saccà, Marcello, additional, Gamucci, Teresa, additional, Berardi, Rossana, additional, Livi, Lorenzo, additional, Ficorella, Corrado, additional, Natoli, Clara, additional, Cortesi, Enrico, additional, Generali, Daniele, additional, Verde, Nicla La, additional, Cassano, Alessandra, additional, Bria, Emilio, additional, Moscetti, Luca, additional, Michelotti, Andrea, additional, Adamo, Vincenzo, additional, Zamagni, Claudio, additional, Tonini, Giuseppe, additional, Barchiesi, Giacomo, additional, Mazzotta, Marco, additional, Marinelli, Daniele, additional, Tomao, Silverio, additional, Marchetti, Paolo, additional, Valerio, Maria Rosaria, additional, Mirabelli, Rosanna, additional, Russo, Antonio, additional, Fabbri, Maria Agnese, additional, D'Ostilio, Nicola, additional, Veltri, Enzo, additional, Corsi, Domenico, additional, Garrone, Ornella, additional, Paris, Ida, additional, Sarobba, Giuseppina, additional, Giotta, Francesco, additional, Garufi, Carlo, additional, Cazzaniga, Marina, additional, Medico, Pietro Del, additional, Roselli, Mario, additional, Sanguineti, Giuseppe, additional, Sperduti, Isabella, additional, Sapino, Anna, additional, De Maria, Ruggero, additional, Leonetti, Carlo, additional, Leo, Angelo Di, additional, Ciliberto, Gennaro, additional, Falcioni, Rita, additional, and Vici, Patrizia, additional

Published
2020
Full Text
View/download PDF

64. Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials

Author

Marinelli, Daniele, primary, Mazzotta, Marco, additional, Pizzuti, Laura, additional, Krasniqi, Eriseld, additional, Gamucci, Teresa, additional, Natoli, Clara, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Tomao, Silverio, additional, Sperduti, Isabella, additional, Sanguineti, Giuseppe, additional, Botticelli, Andrea, additional, Fabbri, Agnese, additional, Botti, Claudio, additional, Ciliberto, Gennaro, additional, Barba, Maddalena, additional, and Vici, Patrizia, additional

Published
2020
Full Text
View/download PDF

65. Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes

Author

Mazzotta, Marco, primary, Filetti, Marco, additional, Occhipinti, Mario, additional, Marinelli, Daniele, additional, Scalera, Stefano, additional, Terrenato, Irene, additional, Sperati, Francesca, additional, Pallocca, Matteo, additional, Rizzo, Francesco, additional, Gelibter, Alain, additional, Botticelli, Andrea, additional, Scafetta, Giorgia, additional, Di Napoli, Arianna, additional, Krasniqi, Eriseld, additional, Pizzuti, Laura, additional, Barba, Maddalena, additional, Carpano, Silvia, additional, Vici, Patrizia, additional, Fanciulli, Maurizio, additional, De Nicola, Francesca, additional, Ciuffreda, Ludovica, additional, Goeman, Frauke, additional, De Maria, Ruggero, additional, Vecchione, Andrea, additional, Giusti, Raffaele, additional, Ciliberto, Gennaro, additional, Marchetti, Paolo, additional, and Maugeri-Saccà, Marcello, additional

Published
2020
Full Text
View/download PDF

67. Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives

Author

Barchiesi, Giacomo, primary, Mazzotta, Marco, additional, Krasniqi, Eriseld, additional, Pizzuti, Laura, additional, Marinelli, Daniele, additional, Capomolla, Elisabetta, additional, Sergi, Domenico, additional, Amodio, Antonella, additional, Natoli, Clara, additional, Gamucci, Teresa, additional, Vizza, Enrico, additional, Marchetti, Paolo, additional, Botti, Claudio, additional, Sanguineti, Giuseppe, additional, Ciliberto, Gennaro, additional, Barba, Maddalena, additional, and Vici, Patrizia, additional

Published
2020
Full Text
View/download PDF

68. Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial

Author

Pizzuti, Laura, primary, Krasniqi, Eriseld, additional, Mandoj, Chiara, additional, Marinelli, Daniele, additional, Sergi, Domenico, additional, Capomolla, Elisabetta, additional, Paoletti, Giancarlo, additional, Botti, Claudio, additional, Kayal, Ramy, additional, Ferranti, Francesca Romana, additional, Sperduti, Isabella, additional, Perracchio, Letizia, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Ciliberto, Gennaro, additional, Barchiesi, Giacomo, additional, Mazzotta, Marco, additional, Barba, Maddalena, additional, Conti, Laura, additional, and Vici, Patrizia, additional

Published
2020
Full Text
View/download PDF

69. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence

Author

Krasniqi, Eriseld, primary, Pizzuti, Laura, additional, Barchiesi, Giacomo, additional, Sergi, Domenico, additional, Carpano, Silvia, additional, Botti, Claudio, additional, Kayal, Ramy, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Botticelli, Andrea, additional, Marinelli, Daniele, additional, Gamucci, Teresa, additional, Natoli, Clara, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Tomao, Silverio, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, Michelotti, Aandrea, additional, Mentuccia, Lucia, additional, Vaccaro, Aangela, additional, Magnolfi, Emanuela, additional, Gelibter, Alain, additional, Magri, Valentina, additional, Cortesi, Enrico, additional, D’Onofrio, Loretta, additional, Cassano, Alessandra, additional, Cazzaniga, Marina, additional, Moscetti, Luca, additional, Fabbri, Agnese, additional, Scinto, Angelo Fedele, additional, Corsi, Domenico, additional, Carbognin, Luisa, additional, Bria, Emilio, additional, La Verde, Nicla, additional, Garufi, Carlo, additional, Di Stefano, Pia, additional, Mirabelli, Rossana, additional, Veltri, Enzo, additional, Paris, Ida, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Landucci, Elisa, additional, Ficorella, Corrado, additional, Roselli, Mario, additional, Adamo, Vincenzo, additional, Ricciardi, Giuseppina, additional, Russo, Antonio, additional, Valerio, Maria Rosaria, additional, Berardi, Rossana, additional, Pistelli, Mirco, additional, Cannita, Katia, additional, Zamagni, Claudio, additional, Garrone, Ornella, additional, Baldini, Editta, additional, Livi, Lorenzo, additional, Meattini, Icro, additional, Del Medico, Pietro, additional, Generali, Daniele, additional, De Maria, Ruggero, additional, Risi, Emanuela, additional, Ciliberto, Gennaro, additional, Villa, Alice, additional, Sperduti, Isabella, additional, Mazzotta, Marco, additional, Barba, Maddalena, additional, Giordano, Antonio, additional, and Vici, Patrizia, additional

Published
2020
Full Text
View/download PDF

74. Supp_Table_1 – Supplemental material for Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting

Author

Benedetto, Anna Di, Ercolani, Cristiana, Pizzuti, Laura, Angelucci, Domenico, Sergi, Domenico, Marinelli, Camilla, Iezzi, Laura, Sperati, Francesca, Terrenato, Irene, Mazzotta, Marco, Mariani, Luciano, Vizza, Enrico, Paoletti, Giancarlo, Tomao, Silverio, Maugeri-Saccà, Marcello, Barba, Maddalena, Tinari, Nicola, Natoli, Clara, Ciliberto, Gennaro, Grassadonia, Antonino, and Vici, Patrizia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, Supp_Table_1 for Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting by Anna Di Benedetto, Cristiana Ercolani, Laura Pizzuti, Domenico Angelucci, Domenico Sergi, Camilla Marinelli, Laura Iezzi, Francesca Sperati, Irene Terrenato, Marco Mazzotta, Luciano Mariani, Enrico Vizza, Giancarlo Paoletti, Silverio Tomao, Marcello Maugeri-Saccà, Maddalena Barba, Nicola Tinari, Clara Natoli, Gennaro Ciliberto, Antonino Grassadonia and Patrizia Vici in Therapeutic Advances in Medical Oncology

Published
2019
Full Text
View/download PDF

75. Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis

Author

Aki, Elie A., Kamath, Ganesh, Yosuico, Victor, Kim, Seo Young, Barba, Maddalena, Sperati, Francesca, Cook, Deborah J., and Schunemann, Holger J.

Subjects
Blood clot -- Risk factors, Blood clot -- Prevention, Blood clot -- Research, Thrombosis -- Risk factors, Thrombosis -- Prevention, Thrombosis -- Research, Central venous catheters -- Complications and side effects, Cancer -- Care and treatment, Cancer -- Complications and side effects, Anticoagulants (Medicine) -- Dosage and administration, Anticoagulants (Medicine) -- Research, Health
Published
2008

77. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

Author

Pizzuti, Laura, Giordano, Antonio, Michelotti, Andrea, Mazzotta, Marco, Natoli, Clara, Gamucci, Teresa, De Angelis, Claudia, Landucci, Elisabetta, Diodati, Lucrezia, Iezzi, Laura, Mentuccia, Lucia, Fabbri, Agnese, Barba, Maddalena, Sanguineti, Giuseppe, Marchetti, Paolo, Tomao, Silverio, Mariani, Luciano, Paris, Ida, Lorusso, Vito, Vallarelli, Simona, Cassano, Alessandra, Airoldi, Francesca, Orlandi, Armando, Moscetti, Luca, Sergi, Domenico, Sarobba, Maria Giuseppina, Tonini, Giuseppe, Santini, Daniele, Sini, Valentina, Veltri, Enzo, Vaccaro, Angela, Ferrari, Laura, De Tursi, Michele, Tinari, Nicola, Grassadonia, Antonino, Greco, Filippo, Botticelli, Andrea, La Verde, Nicla, Zamagni, Claudio, Rubino, Daniela, Cortesi, Enrico, Magri, Valentina, Pomati, Giulia, Scagnoli, Simone, Capomolla, Elisabetta, Kayal, Ramy, Scinto, Angelo Fedele, Corsi, Domenico Cristiano, Cazzaniga, Marina, Laudadio, Lucio, Forciniti, Samantha, Mancini, Maria, Carbognin, Luisa, Seminara, Patrizia, Barni, Sandro, Samaritani, Riccardo, Roselli, Mario, Portarena, Ilaria, Dello Russo, Antonio, Ficorella, Corrado, Cannita, Katia, Carpano, Silvia, Pistelli, Mirco, Berardi, Rossana, De Maria Marchiano, Ruggero, Sperduti, Isabella, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Orlandi, Armando (ORCID:0000-0001-5253-4678), Corsi, Domenico, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Pizzuti, Laura, Giordano, Antonio, Michelotti, Andrea, Mazzotta, Marco, Natoli, Clara, Gamucci, Teresa, De Angelis, Claudia, Landucci, Elisabetta, Diodati, Lucrezia, Iezzi, Laura, Mentuccia, Lucia, Fabbri, Agnese, Barba, Maddalena, Sanguineti, Giuseppe, Marchetti, Paolo, Tomao, Silverio, Mariani, Luciano, Paris, Ida, Lorusso, Vito, Vallarelli, Simona, Cassano, Alessandra, Airoldi, Francesca, Orlandi, Armando, Moscetti, Luca, Sergi, Domenico, Sarobba, Maria Giuseppina, Tonini, Giuseppe, Santini, Daniele, Sini, Valentina, Veltri, Enzo, Vaccaro, Angela, Ferrari, Laura, De Tursi, Michele, Tinari, Nicola, Grassadonia, Antonino, Greco, Filippo, Botticelli, Andrea, La Verde, Nicla, Zamagni, Claudio, Rubino, Daniela, Cortesi, Enrico, Magri, Valentina, Pomati, Giulia, Scagnoli, Simone, Capomolla, Elisabetta, Kayal, Ramy, Scinto, Angelo Fedele, Corsi, Domenico Cristiano, Cazzaniga, Marina, Laudadio, Lucio, Forciniti, Samantha, Mancini, Maria, Carbognin, Luisa, Seminara, Patrizia, Barni, Sandro, Samaritani, Riccardo, Roselli, Mario, Portarena, Ilaria, Dello Russo, Antonio, Ficorella, Corrado, Cannita, Katia, Carpano, Silvia, Pistelli, Mirco, Berardi, Rossana, De Maria Marchiano, Ruggero, Sperduti, Isabella, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Orlandi, Armando (ORCID:0000-0001-5253-4678), Corsi, Domenico, and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)

Abstract

Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8–16) and median overall survival was 24 months (95% CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.

Published
2019

78. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

Author

Gamucci, Teresa, Pizzuti, Laura, Natoli, Clara, Mentuccia, Lucia, Sperduti, Isabella, Barba, Maddalena, Sergi, Domenico, Iezzi, Laura, Maugeri-Saccà, Marcello, Vaccaro, Angela, Magnolfi, Emanuela, Gelibter, Alain, Barchiesi, Giacomo, Magri, Valentina, D’Onofrio, Loretta, Cassano, Alessandra, Rossi, Ernesto, Botticelli, Andrea, Moscetti, Luca, Omarini, Claudia, Fabbri, Maria Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Mazzotta, Marco, Bria, Emilio, Foglietta, Jennifer, Samaritani, Riccardo, Garufi, Carlo, Mariani, Luciano, Barni, Sandro, Mirabelli, Rosanna, Sarmiento, Roberta, Graziano, Vincenzo, Santini, Daniele, Marchetti, Paolo, Tonini, Giuseppe, Di Lauro, Luigi, Sanguineti, Giuseppe, Paoletti, Giancarlo, Tomao, Silverio, De Maria Marchiano, Ruggero, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Latorre, Agnese, Giordano, Antonio, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Corsi, Domenico Cristiano, Bria, Emilio (ORCID:0000-0002-2333-704X), De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Gamucci, Teresa, Pizzuti, Laura, Natoli, Clara, Mentuccia, Lucia, Sperduti, Isabella, Barba, Maddalena, Sergi, Domenico, Iezzi, Laura, Maugeri-Saccà, Marcello, Vaccaro, Angela, Magnolfi, Emanuela, Gelibter, Alain, Barchiesi, Giacomo, Magri, Valentina, D’Onofrio, Loretta, Cassano, Alessandra, Rossi, Ernesto, Botticelli, Andrea, Moscetti, Luca, Omarini, Claudia, Fabbri, Maria Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Mazzotta, Marco, Bria, Emilio, Foglietta, Jennifer, Samaritani, Riccardo, Garufi, Carlo, Mariani, Luciano, Barni, Sandro, Mirabelli, Rosanna, Sarmiento, Roberta, Graziano, Vincenzo, Santini, Daniele, Marchetti, Paolo, Tonini, Giuseppe, Di Lauro, Luigi, Sanguineti, Giuseppe, Paoletti, Giancarlo, Tomao, Silverio, De Maria Marchiano, Ruggero, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Latorre, Agnese, Giordano, Antonio, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Corsi, Domenico Cristiano, Bria, Emilio (ORCID:0000-0002-2333-704X), and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)

Abstract

We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC) patients to explore the efficacy of first-line treatment with pertuzumab/trastuzumab/taxane in real-world setting. Survival data were analyzed by Kaplan Meier curves and log rank test. Median follow-up, length of pertuzumab/trastuzumab/taxane treatment and of pertuzumab, trastuzumab maintenance were 21, 4 and 15 months, respectively. The response rate was 77.3%, and the clinical benefit rate 93.6%. Median progression-free survival (mPFS) was 21 months, and median overall survival (mOS) was not reached. When comparing patients by trastuzumab-pretreatment, similar PFS were observed, although a longer OS was reached in trastuzumab-naïve patients (p = 0.02). Brain metastases at baseline and their development in course of therapy were associated with significantly shorter PFS (p = 0.0006) and shorter OS, although at a not fully statistically relevant extent (p = 0.06). The addition of maintenance endocrine therapy (ET) to pertuzumab/trastuzumab maintenance was associated with longer PFS (p = 0.0001), although no significant differences were detected in OS (p = 0.31). Results were confirmed by propensity score analysis (p = 0.003 and p = 0.46, respectively). In multivariate models, longer PFS was related to lower Performance Status (PS) (p = 0.07), metastatic stage at diagnosis (p = 0.006) and single metastatic site (p < 0.0001). An OS advantage was observed with lower PS (p < 0.0001), single metastatic site (p = 0.004), no prior exposure to trastuzumab (p = 0.004) and response to pertuzumab-based treatment (p = 0.003). Our results confirm that trastuzumab/pertuzumab/taxane is the standard of care as first-line treatment of patients with HER2-positive ABC even in the real-world setting. Moreover, the double-maintenance therapy (HER2 block and ET) is strongly recommended when feasible.

Published
2019

81. The burden of breast cancer in Italy: mastectomies and quadrantectomies performed between 2001 and 2008 based on nationwide hospital discharge records

Author

Piscitelli Prisco, Barba Maddalena, Crespi Massimo, Di Maio Massimo, Santoriello Antonio, D’Aiuto Massiliamo, Fucito Alfredo, Losco Arturo, Pentimalli Francesca, Maranta Pasquale, Chitano Giovanna, Argentiero Alberto, Neglia Cosimo, Distante Alessandro, Di Tanna Gian luca, Brandi Maria Luisa, Mazza Alfredo, Marino Ignazio R, and Giordano Antonio

Subjects
Hospital discharge records, Breast cancer, Mastectomies, Quadrantectomies, Cancer surveillance, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Where population coverage is limited, the exclusive use of Cancer Registries might limit ascertainment of incident cancer cases. We explored the potentials of Nationwide hospital discharge records (NHDRs) to capture incident breast cancer cases in Italy. Methods We analyzed NHDRs for mastectomies and quadrantectomies performed between 2001 and 2008. The average annual percentage change (AAPC) and related 95% Confidence Interval (CI) in the actual number of mastectomies and quadrantectomies performed during the study period were computed for the full sample and for subgroups defined by age, surgical procedure, macro-area and singular Region. Re-admissions of the same patients were separately presented. Results The overall number of mastectomies decreased, with an AAPC of −2.1% (−2.3 -1.8). This result was largely driven by the values observed for women in the 45 to 64 and 65 to 74 age subgroups (−3.0%, -3.4 -3.6 and −3.3%, -3.8 -2.8, respectively). We observed no significant reduction in mastectomies for women in the remaining age groups. Quadrantectomies showed an overall +4.7 AAPC (95%CI:4.5–4.9), with no substantial differences by age. Analyses by geographical area showed a remarkable decrease in mastectomies, with inter-regional discrepancies possibly depending upon variability in mammography screening coverage and adherence. Quadrantectomies significantly increased, with Southern Regions presenting the highest average rates. Data on repeat admissions within a year revealed a total number of 46,610 major breast surgeries between 2001 and 2008, with an overall +3.2% AAPC (95%CI:2.8-3.6). Conclusions In Italy, NHDRs might represent a valuable supplemental data source to integrate Cancer Registries in cancer surveillance.

Published
2012
Full Text
View/download PDF

82. MOESM2 of Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy

Author

Melucci, Elisa, Casini, Beatrice, Ronchetti, Livia, Pizzuti, Laura, Sperati, Francesca, Pallocca, Matteo, Nicola, Francesca De, Goeman, Frauke, Gallo, Enzo, Amoreo, Carla, Sergi, Domenico, Terrenato, Irene, Vici, Patrizia, Lauro, Luigi Di, Diodoro, Maria, Pescarmona, Edoardo, Barba, Maddalena, Mazzotta, Marco, Mottolese, Marcella, Fanciulli, Maurizio, Ciliberto, Gennaro, Maria, Ruggero De, Buglioni, Simonetta, and Maugeri-SaccĂ, Marcello

Abstract

Additional file 2. Representative examples of immunohistochemical expression of TAZ and YAP in gastric cancer. Two cases are presented with combined nuclear expression of both TAZ and YAP (Aâ D).

Published
2018
Full Text
View/download PDF

83. MOESM1 of Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer

Author

Pallocca, Matteo, Goeman, Frauke, Nicola, Francesca De, Melucci, Elisa, Sperati, Francesca, Terrenato, Irene, Pizzuti, Laura, Casini, Beatrice, Gallo, Enzo, Amoreo, Carla, Vici, Patrizia, Lauro, Luigi Di, Buglioni, Simonetta, Diodoro, Maria, Pescarmona, Edoardo, Mazzotta, Marco, Barba, Maddalena, Fanciulli, Maurizio, Maria, Ruggero De, Ciliberto, Gennaro, and Maugeri-SaccĂ, Marcello

Abstract

Additional file 1. Baseline characteristics of gastric cancer (GC) patients included in this study (N = 83).

Published
2018
Full Text
View/download PDF

84. MOESM1 of Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting

Author

Mandoj, Chiara, Pizzuti, Laura, Sergi, Domenico, Sperduti, Isabella, Mazzotta, Marco, Lauro, Luigi, Amodio, Antonella, Carpano, Silvia, Benedetto, Anna, Botti, Claudio, Ferranti, Francesca, Antenucci, Anna, D’Alessandro, Maria, Marchetti, Paolo, Tomao, Silverio, Sanguineti, Giuseppe, Giordano, Antonio, Maugeri-SaccĂ, Marcello, Ciliberto, Gennaro, Conti, Laura, Vici, Patrizia, and Barba, Maddalena

Subjects
skin and connective tissue diseases
Abstract

Additional file 1: Table S1. Multivariate analysis for disease-free survival in a subset of 62 breast cancer patients.

Published
2018
Full Text
View/download PDF

85. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting

Author

Pizzuti, Laura, primary, Krasniqi, Eriseld, additional, Barchiesi, Giacomo, additional, Della Giulia, Marina, additional, Izzo, Fiorentino, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Mazzotta, Marco, additional, Giusti, Raffaele, additional, Botticelli, Andrea, additional, Gamucci, Teresa, additional, Natoli, Clara, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Iezzi, Laura, additional, Tomao, Silverio, additional, Tomao, Federica, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, Astone, Antonio, additional, Michelotti, Andrea, additional, De Angelis, Claudia, additional, Mentuccia, Lucia, additional, Vaccaro, Angela, additional, Magnolfi, Emanuela, additional, Gelibter, Alain, additional, Magri, Valentina, additional, Cortesi, Enrico, additional, D'Onofrio, Loretta, additional, Cassano, Alessandra, additional, Rossi, Ernesto, additional, Cazzaniga, Marina, additional, Moscetti, Luca, additional, Omarini, Claudia, additional, Piacentini, Federico, additional, Fabbri, Maria A., additional, Scinto, Angelo F., additional, Corsi, Domenico, additional, Carbognin, Luisa, additional, Bria, Emilio, additional, La Verde, Nicla, additional, Samaritani, Riccardo, additional, Garufi, Carlo, additional, Barni, Sandro, additional, Mirabelli, Rosanna, additional, Sarmiento, Roberta, additional, Veltri, Enzo M., additional, D'Auria, Giuliana, additional, Paris, Ida, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Cardillo, Franca, additional, Landucci, Elisabetta, additional, Mauri, Maria, additional, Ficorella, Corrado, additional, Roselli, Mario, additional, Adamo, Vincenzo, additional, Ricciardi, Giuseppina R.R., additional, Russo, Antonio, additional, Berardi, Rossana, additional, Pistelli, Mirco, additional, Fiorio, Elena, additional, Cannita, Katia, additional, Sini, Valentina, additional, D'Ostilio, Nicola, additional, Foglietta, Jennifer, additional, Greco, Filippo, additional, Zamagni, Claudio, additional, Garrone, Ornella, additional, Di Cocco, Barbara, additional, Baldini, Editta, additional, Livi, Lorenzo, additional, Desideri, Isacco, additional, Meattini, Icro, additional, Sarobba, Giuseppina, additional, Del Medico, Pietro, additional, De Tursi, Michele, additional, Generali, Daniele, additional, De Maria, Ruggero, additional, Risi, Emanuela, additional, Ciliberto, Gennaro, additional, Sperduti, Isabella, additional, Villa, Alice, additional, Barba, Maddalena, additional, Di Leo, Angelo, additional, and Vici, Patrizia, additional

Published
2019
Full Text
View/download PDF

86. Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer

Author

Maselli, Angela, primary, Parlato, Stefania, additional, Puglisi, Rossella, additional, Raggi, Carla, additional, Spada, Massimo, additional, Macchia, Daniele, additional, Pontecorvi, Giada, additional, Iessi, Elisabetta, additional, Pagano, Maria Teresa, additional, Cirulli, Francesca, additional, Gabriele, Lucia, additional, Carè, Alessandra, additional, Vici, Patrizia, additional, Pizzuti, Laura, additional, Barba, Maddalena, additional, Matarrese, Paola, additional, Pierdominici, Marina, additional, and Ortona, Elena, additional

Published
2019
Full Text
View/download PDF

88. Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study

Author

Grassadonia, Antonino, primary, Di Marino, Pietro, additional, Ficorella, Corrado, additional, Cortellini, Alessio, additional, Cannita, Katia, additional, Parisi, Alessandro, additional, Gamucci, Teresa, additional, Zoratto, Federica, additional, Vici, Patrizia, additional, Barba, Maddalena, additional, Porreca, Ettore, additional, Neri, Matteo, additional, Veronese, Angelo, additional, Natoli, Clara, additional, De Tursi, Michele, additional, and Tinari, Nicola, additional

Published
2019
Full Text
View/download PDF

89. Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting

Author

Di Benedetto, Anna, primary, Ercolani, Cristiana, additional, Pizzuti, Laura, additional, Angelucci, Domenico, additional, Sergi, Domenico, additional, Marinelli, Camilla, additional, Iezzi, Laura, additional, Sperati, Francesca, additional, Terrenato, Irene, additional, Mazzotta, Marco, additional, Mariani, Luciano, additional, Vizza, Enrico, additional, Paoletti, Giancarlo, additional, Tomao, Silverio, additional, Maugeri-Saccà, Marcello, additional, Barba, Maddalena, additional, Tinari, Nicola, additional, Natoli, Clara, additional, Ciliberto, Gennaro, additional, Grassadonia, Antonino, additional, and Vici, Patrizia, additional

Published
2019
Full Text
View/download PDF

90. Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios

Author

Pizzuti, Laura, primary, Krasniqi, Eriseld, additional, Barchiesi, Giacomo, additional, Mazzotta, Marco, additional, Barba, Maddalena, additional, Amodio, Antonella, additional, Massimiani, Gioia, additional, Pelle, Fabio, additional, Kayal, Ramy, additional, Vizza, Enrico, additional, Grassadonia, Antonino, additional, Tomao, Silverio, additional, Venuti, Aldo, additional, Gamucci, Teresa, additional, Marchetti, Paolo, additional, Natoli, Clara, additional, Sanguineti, Giuseppe, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2019
Full Text
View/download PDF

91. An instrument to assess quality of life in relation to nutrition: item generation, item reduction and initial validation

Author

Akl Elie A, Melegari Camilla, Santesso Nancy, Barba Maddalena, Sperati Francesca, Schünemann Holger J, Guyatt Gordon, and Muti Paola

Subjects
Computer applications to medicine. Medical informatics, R858-859.7
Abstract

Abstract Background It is arguable that modification of diet, given its potential for positive health outcomes, should be widely advocated and adopted. However, food intake, as a basic human need, and its modification may be accompanied by sensations of both pleasure and despondency and may consequently affect to quality of life (QoL). Thus, the feasibility and success of dietary changes will depend, at least partly, on whether potential negative influences on QoL can be avoided. This is of particular importance in the context of dietary intervention studies and in the development of new food products to improve health and well being. Instruments to measure the impact of nutrition on quality of life in the general population, however, are few and far between. Therefore, the aim of this project was to develop an instrument for measuring QoL related to nutrition in the general population. Methods and results We recruited participants from the general population and followed standard methodology for quality of life instrument development (identification of population, item selection, n = 24; item reduction, n = 81; item presentation, n = 12; pretesting of questionnaire and initial validation, n = 2576; construct validation n = 128; and test-retest reliability n = 20). Of 187 initial items, 29 were selected for final presentation. Factor analysis revealed an instrument with 5 domains. The instrument demonstrated good cross-sectional divergent and convergent construct validity when correlated with scores of the 8 domains of the SF-36 (ranging from -0.078 to 0.562, 19 out of 40 tested correlations were statistically significant and 24 correlations were predicted correctly) and good test-retest reliability (intra-class correlation coefficients from 0.71 for symptoms to 0.90). Conclusions We developed and validated an instrument with 29 items across 5 domains to assess quality of life related to nutrition and other aspects of food intake. The instrument demonstrated good face and construct validity as well as good reliability. Future work will focus on the evaluation of longitudinal construct validity and responsiveness.

Published
2010
Full Text
View/download PDF

92. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis

Author

Blandino Giovanni, Westerlind Kim C, Stranges Saverio, Grioni Sara, Sperati Francesca, Schünemann Holger J, Yang Li, Barba Maddalena, Gallucci Michele, Lauria Rossella, Malorni Luca, and Muti Paola

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Objective To investigate prostate cancer (Pca) risk in relation to estrogen metabolism, expressed as urinary 2-hydroxyestrone (2-OHE1), 16α-hydroxyestrone (16α-OHE1) and 2-OHE1 to 16α-OHE1 ratio. Methods We conducted a case-control study within the Western New York Health Cohort Study (WNYHCS) from 1996 to 2001. From January 2003 through September 2004, we completed the re-call and follow-up of 1092 cohort participants. Cases (n = 26) and controls (n = 110) were matched on age, race and recruitment period according to a 1:4 ratio. We used the unconditional logistic regression to compute crude and adjusted odds ratios (OR) and 95% confident interval (CI) of Pca in relation to 2-OHE1, 16αOHE1 and 2-OHE1 to 16α-OHE1 by tertiles of urine concentrations (stored in a biorepository for an average of 4 years). We identified age, race, education and body mass index as covariates. We also conducted a systematic review of the literature which revealed no additional studies, but we pooled the results from this study with those from a previously conducted case-control study using the DerSimonian-Laird random effects method. Results We observed a non-significant risk reduction in the highest tertile of 2-OHE1 (OR 0.72, 95% CI 0.25-2.10). Conversely, the odds in the highest tertile of 16α-OHE1 showed a non-significant risk increase (OR 1.76 95% CI 0.62-4.98). There was a suggestion of reduced Pca risk for men in the highest tertile of 2-OHE1 to 16α-OHE1 ratio (OR 0.56, 95% CI 0.19-1.68). The pooled estimates confirmed the association between an increased Pca risk and higher urinary levels of 16α-OHE1 (third vs. first tertile: OR 1.82, 95% CI 1.09-3.05) and the protective effect of a higher 2-OHE 1 to 16α-OHE1 ratio (third vs. first tertile: OR 0.53, 95% CI 0.31-0.90). Conclusion Our study and the pooled results provide evidence for a differential role of the estrogen hydroxylation pathway in Pca development and encourage further study.

Published
2009
Full Text
View/download PDF

93. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review

Author

Sperati Francesca, Terrenato Irene, Rohilla Sandeep, Barba Maddalena, Akl Elie A, Muti Paola, and Schünemann Holger J

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Cancer and its therapies increase the risk of venous thromboembolism. Compared to patients without cancer, patients with cancer anticoagulated for venous thromboembolism are more likely to develop recurrent thrombotic events and major bleeding. Addressing all important outcomes including harm is of great importance to make evidence based health care decisions. The objective of this study was to compare low molecular weight heparin (LMWH) and oral anticoagulants (vitamin K antagonist (VKA) and ximelagatran) for the long term treatment of venous thromboembolism in patients with cancer. Methods A systematic review of the medical literature. We followed the Cochrane Collaboration methodology for conducting systematic reviews. We assessed methodological quality for each outcome by grading the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. Results Eight randomized controlled trials (RCTs) were eligible and reported data for patients with cancer. The quality of evidence was low for death and moderate for recurrent venous thromboembolism. LMWH, compared to VKA provided no statistically significant survival benefit (Hazard ratio (HR) = 0.96; 95% CI 0.81 to 1.14) but a statistically significant reduction in venous thromboembolism (HR = 0.47; 95% (Confidence Interval (CI) = 0.32 to 0.71). There was no statistically significant difference between LMWH and VKA in bleeding outcomes (RR = 0.91; 95% CI = 0.64 to 1.31) or thrombocytopenia (RR = 1.02; 95% CI = 0.60 to 1.74). Conclusion For the long term treatment of venous thromboembolism in patients with cancer, LMWH compared to VKA reduces venous thromboembolism but not death.

Published
2008
Full Text
View/download PDF

94. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review

Author

Yosuico Victor, Middeldorp Saskia, Kuipers Saskia, Kim Seo, Kamath Ganesh, Barba Maddalena, van Doormaal Frederiek F, Akl Elie A, Dickinson Heather O, and Schünemann Holger J

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background To determine the efficacy and safety of heparin (unfractionated heparin (UFH) or low-molecular-weight-heparin (LMWH)) and fondaparinux in improving the survival of patients with cancer. Methods We conducted in January 2007 a comprehensive search for relevant randomized clinical trials (RCTs). We used a standardized form to extract in duplicate data on methodological quality, participants, interventions and outcomes of interest including all cause mortality, thromboembolic events, and bleeding events. We assessed the methodological quality for each outcome by grading the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology Results Of 3986 identified citations, we included 5 RCTs, none of which evaluated fondaparinux. The quality of evidence was moderate for survival, low for major and minor bleeding, and very low for DVT. Heparin therapy was associated with a statistically and clinically significant survival benefit (hazard ratio (HR) = 0.77; 95%CI = 0.65–0.91). In subgroup analyses, patients with limited small cell lung cancer experienced a clear survival benefit (HR = 0.56; 95%CI = 0.38–0.83). The survival benefit was not statistically significant for either patients with extensive small cell lung cancer (HR = 0.80; 95%CI = 0.60–1.06) or patients with advanced cancer (HR = 0.84; 95%CI = 0.68–1.03). The increased risk of bleeding with heparin was not statistically significant (relative risk (RR) = 1.78; 95%CI = 0.73–4.38). Conclusion This review suggests a survival benefit of heparin in cancer patients in general, and in patients with limited small cell lung cancer in particular.

Published
2008
Full Text
View/download PDF

95. GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer

Author

Pizzuti, Laura, Sergi, Domenico, Mandoj, Chiara, Antoniani, Barbara, Sperati, Francesca, Chirico, Andrea, Di Lauro, Luigi, Valle, Mario, Garofalo, Alfredo, Vizza, Enrico, Corrado, Giacomo, Tomao, Federica, Rinaldi, Massimo, Carpano, Silvia, Maugeri-Saccà, Marcello, Conti, Laura, Digiesi, Giovanna, Marchetti, Paolo, De Maria Marchiano, Ruggero, Giordano, Antonio, Barba, Maddalena, Carosi, Maria A., Vici, Patrizia, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Pizzuti, Laura, Sergi, Domenico, Mandoj, Chiara, Antoniani, Barbara, Sperati, Francesca, Chirico, Andrea, Di Lauro, Luigi, Valle, Mario, Garofalo, Alfredo, Vizza, Enrico, Corrado, Giacomo, Tomao, Federica, Rinaldi, Massimo, Carpano, Silvia, Maugeri-Saccà, Marcello, Conti, Laura, Digiesi, Giovanna, Marchetti, Paolo, De Maria Marchiano, Ruggero, Giordano, Antonio, Barba, Maddalena, Carosi, Maria A., Vici, Patrizia, and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)

Abstract

In recent years, the poorly remarkable goals achieved in terms of patients’ important outcomes for ovarian cancer have fueled our interest toward the study of its metabolic roots. Within this research pipeline, we assessed the association between the expression of the glucose transporter GLUT1, as expressed at the tumor tissue level, and circulating pre-surgical levels of fasting glucose in a case series including data from 40 patients with high FIGO stage serous ovarian cancer. Patients who provided data to the current analysis were randomly selected from a larger cohort. To our purposes, the procedures related to serum and tissue collection, storage and biomarker assessment were highly standardized and centralized at the institutional laboratories. The GLUT1 antibody SPM498 SPRING (REF. E13810) was used at a 1:500 dilution in 2 µm slides. Staining for GLUT1 was observed at the cell membrane level in all the cases assessed, but strong staining was described in 29 (72.5%) of them. The agreement between the two independent reviewers was 100%. Strong GLUT1 staining was inversely associated with circulating levels of fasting glucose, with a particularly striking difference for patients in the lowest fasting glucose tertile (p = 0.044). These results support the biological plausibility of the association of interest. If confirmed in larger studies, our findings may help clarify the potentials of biomarkers related to energy metabolism in terms of prognosis definition, treatment assignment, and outcome interpretation for patients with high FIGO stage serous ovarian cancer.

Published
2018

96. Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy

Author

Melucci, Elisa, Casini, Beatrice, Ronchetti, Livia, Pizzuti, Laura, Sperati, Francesca, Pallocca, Matteo, De Nicola, Francesca, Goeman, Frauke, Gallo, Enzo, Amoreo, Carla Azzurra, Sergi, Domenico, Terrenato, Irene, Vici, Patrizia, Di Lauro, Luigi, Diodoro, Maria Grazia, Pescarmona, Edoardo, Barba, Maddalena, Mazzotta, Marco, Mottolese, Marcella, Fanciulli, Maurizio, Ciliberto, Gennaro, De Maria Marchiano, Ruggero, Buglioni, Simonetta, Maugeri-Saccà, Marcello, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Melucci, Elisa, Casini, Beatrice, Ronchetti, Livia, Pizzuti, Laura, Sperati, Francesca, Pallocca, Matteo, De Nicola, Francesca, Goeman, Frauke, Gallo, Enzo, Amoreo, Carla Azzurra, Sergi, Domenico, Terrenato, Irene, Vici, Patrizia, Di Lauro, Luigi, Diodoro, Maria Grazia, Pescarmona, Edoardo, Barba, Maddalena, Mazzotta, Marco, Mottolese, Marcella, Fanciulli, Maurizio, Ciliberto, Gennaro, De Maria Marchiano, Ruggero, Buglioni, Simonetta, Maugeri-Saccà, Marcello, and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)

Abstract

Background: An extensive crosstalk co-regulates the Hippo and Wnt pathway. Preclinical studies revealed that the Hippo transducers YAP/TAZ mediate a number of oncogenic functions in gastric cancer (GC). Moreover, comprehensive characterization of GC demonstrated that the Wnt pathway is targeted by oncogenic mutations. On this ground, we hypothesized that YAP/TAZ- and Wnt-related biomarkers may predict clinical outcomes in GC patients treated with chemotherapy. Methods: In the present study, we included 86 patients with advanced GC treated with first-line chemotherapy in prospective phase II trials or in routine clinical practice. Tissue samples were immunostained to evaluate the expression of YAP/TAZ. Mutational status of key Wnt pathway genes (CTNNB1, APC and FBXW7) was assessed by targeted DNA next-generation sequencing (NGS). Survival curves were estimated and compared by the Kaplan-Meier product-limit method and the log-rank test, respectively. Variables potentially affecting progression-free survival (PFS) were verified in univariate Cox proportional hazard models. The final multivariate Cox models were obtained with variables testing significant at the univariate analysis, and by adjusting for all plausible predictors of the outcome of interest (PFS). Results: We observed a significant association between TAZ expression and Wnt mutations (Chi-squared p = 0.008). Combined TAZ expression and Wnt mutations (TAZpos/WNTmut) was more frequently observed in patients with the shortest progression-free survival (negative outliers) (Fisher p = 0.021). Uni-and multivariate Cox regression analyses revealed that patients whose tumors harbored the TAZpos/WNTmutsignature had an increased risk of disease progression (univariate Cox: HR 2.27, 95% CI 1.27-4.05, p = 0.006; multivariate Cox: HR 2.73, 95% CI 1.41-5.29, p = 0.003). Finally, the TAZpos/WNTmutsignature negatively impacted overall survival. Conclusions: Collectively, our findings indicate that the oncogenic YAP/TAZ-Wn

Published
2018

97. Lifetime total and beverage specific - alcohol intake and prostate cancer risk: a case-control study

Author

Carruba Giuseppe, De Placido Sabino, Fuhrman Barbara, Stranges Saverio, Schünemann Holger J, McCann Susan E, Barba Maddalena, Freudenheim Jo L, Trevisan Maurizio, Russell Marcia, Nochajski Tom, and Muti Paola

Subjects
Nutrition. Foods and food supply, TX341-641, Nutritional diseases. Deficiency diseases, RC620-627
Abstract

Abstract Background We investigated lifetime alcohol consumption and prostate cancer risk in a case-control study conducted in Buffalo, NY (1998–2001). Methods The study included 88 men, aged 45 to 85 years with incident, histologically-confirmed prostate cancer and 272 controls. We conducted extensive in-person interviews regarding lifetime alcohol consumption and other epidemiologic data. Results Prostate cancer risk was not associated with lifetime intake of total and beverage specific ethanol. In addition we found no association with number of drinks per day (average drinks per day over the lifetime) or drinks per drinking day (average drinks per day on drinking days only over the lifetime). However, we observed an inverse association with the total number of drinking years. Men in the lowest tertile of total drinking years had a two-fold prostate cancer risk than men in the highest tertile (OR 2.16, 95% CI 0.98–4.78, p for trend Conclusion Our results suggest that alcohol intake distribution across lifetime may play a more important role in prostate cancer etiology than total lifetime consumption.

Published
2004
Full Text
View/download PDF

98. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience

Author

Vici, Patrizia, Pizzuti, Laura, Michelotti, Andrea, Sperduti, Isabella, Natoli, Clara, Mentuccia, Lucia, Di Lauro, Luigi, Sergi, Domenico, Marchetti, Paolo, Santini, Daniele, Magnolfi, Emanuela, Iezzi, Laura, Moscetti, Luca, Fabbri, Agnese, Cassano, Alessandra, Grassadonia, Antonino, Omarini, Claudia, Piacentini, Federico, Botticelli, Andrea, Bertolini, Ilaria, Scinto, Angelo Fedele, Zampa, Germano, Mauri, Maria, D'Onofrio, Loretta, Sini, Valentina, Barba, Maddalena, Maugeri-saccã&nbsp, Marcello, Rossi, Ernesto, Landucci, Elisabetta, Tomao, Silverio, Alberti, Antonio Maria, Giotta, Francesco, Ficorella, Corrado, Adamo, Vincenzo, Russo, Antonio, Lorusso, Vito, Cannita, Katia, Barni, Sandro, Laudadio, Lucio, Greco, Filippo, Garrone, Ornella, Della Giulia, Marina, Marolla, Paolo, Sanguineti, Giuseppe, Di Cocco, Barbara, Ciliberto, Gennaro, De Maria, Ruggero, Gamucci, Teresa, Vici, P., Pizzuti, L., Michelotti, A., Sperduti, I., Natoli, C., Mentuccia, L., Di Lauro, L., Sergi, D., Marchetti, P., Santini, D., Magnolfi, E., Iezzi, L., Moscetti, L., Fabbri, A., Cassano, A., Grassadonia, A., Omarini, C., Piacentini, F., Botticelli, A., Bertolini, I., Scinto, A., Zampa, G., Mauri, M., D'Onofrio, L., Sini, V., Barba, M., Maugeri-Saccà , M., Rossi, E., Landucci, E., Tomao, S., Alberti, A., Giotta, F., Ficorella, C., Adamo, V., Russo, A., Lorusso, V., Cannita, K., Barni, S., Laudadio, L., Greco, F., Garrone, O., Della Giulia, M., Marolla, P., Sanguineti, G., Di Cocco, B., Ciliberto, G., De Maria, R., and Gamucci, T.

Subjects
0301 basic medicine, Oncology, HER2 positive, real-world, medicine.medical_specialty, T-DM1, metastatic breast cancer, previous pertuzumab, Metastatic breast cancer, Previous pertuzumab, Real-world, oncology, ECOG Performance Status, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, Settore MED/04 - PATOLOGIA GENERALE, law, Internal medicine, Medicine, Univariate analysis, Settore MED/06 - ONCOLOGIA MEDICA, business.industry, Cancer, medicine.disease, Log-rank test, trastuzumab, 030104 developmental biology, chemistry, Trastuzumab emtansine, 030220 oncology & carcinogenesis, HER2 positive, Metastatic breast cancer, Previous pertuzumab, Real-world, T-DM1, Oncology, Pertuzumab, business, medicine.drug, Research Paper
Abstract

We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in pertuzumab-pretreated patients. We conducted a retrospective, observational study involving 23 cancer centres, and 250 patients. Survival data were analyzed by Kaplan Meier curves and log rank test. Factors testing significant in univariate analysis were tested in multivariate models. Median follow-up was 15 months and median T-DM1 treatment-length 4 months. Response rate was 41.6%, clinical benefit 60.9%. Median progression-free and median overall survival were 6 and 20 months, respectively. Overall, no differences emerged by pertuzumab pretreatment, with median progression-free and median overall survival of 4 and 17 months in pertuzumab-pretreated (p=0.13), and 6 and 22 months in pertuzumab-naïve patients (p=0.27). Patients who received second-line T-DM1 had median progression-free and median overall survival of 3 and 12 months (p=0.0001) if pertuzumab-pretreated, and 8 and 26 months if pertuzumab-naïve (p=0.06). In contrast, in third-line and beyond, median progression-free and median overall survival were 16 and 18 months in pertuzumab-pretreated (p=0.05) and 6 and 17 months in pertuzumab-naïve patients (p=0.30). In multivariate analysis, lower ECOG performance status was associated with progression-free survival benefit (p < 0.0001), while overall survival was positively affected by lower ECOG PS (p < 0.0001), absence of brain metastases (p 0.05), and clinical benefit (p < 0.0001). Our results are comparable with those from randomized trials. Further studies are warranted to confirm and interpret our data on apparently lower T-DM1 efficacy when given as second-line treatment after pertuzumab, and on the optimal sequence order.

Published
2017

99. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer

Author

Gamucci, Teresa, Mentuccia, Lucia, Natoli, Clara, Sperduti, Isabella, Cassano, Alessandra, Michelotti, Andrea, Di Lauro, Luigi, Sergi, Domenico, Fabi, Alessandra, Sarobba, Maria G., Marchetti, Paolo, Barba, Maddalena, Magnolfi, Emanuela, Maugeri‐Saccà, Marcello, Rossi, Ernesto, Sini, Valentina, Grassadonia, Antonino, Pellegrini, Domenica, Astone, Antonino, Nisticò, Cecilia, Angelini, Franco, Vaccaro, Angela, Pellegrino, Arianna, De Angelis, Claudia, Palleschi, Michela, Moscetti, Luca, Bertolini, Ilaria, Buglioni, Simonetta, Giordano, Antonio, Pizzuti, Laura, and Vici, Patrizia

Subjects
Adult, Paclitaxel, Receptor, ErbB-2, Physiology, Clinical Biochemistry, Breast Neoplasms, Disease-Free Survival, Maintenance Chemotherapy, ErbB-2, 80 and over, Humans, Original Research Article, Neoplasm Metastasis, Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Settore MED/06 - ONCOLOGIA MEDICA, Medicine (all), Cell Biology, Middle Aged, Bevacizumab, Treatment Outcome, Multivariate Analysis, Female, Receptor
Abstract

Bevacizumab in combination with taxanes in HER2‐negative metastatic breast cancer (MBC) patients has shown improved progression‐free survival (PFS), despite the lack of clear overall survival (OS) benefit. We performed a retrospective analysis to evaluate the impact of paclitaxel‐bevacizumab and of maintenance therapy with bevacizumab (BM) and endocrine therapy (ET) in the real‐world practice. We identified 314 HER2‐negative MBC patients treated in 12 cancer centers. Overall, the median PFS and OS were 14 and 40 months, respectively. Among the 254 patients potentially eligible for BM, 183 received BM after paclitaxel discontinuation until progression/toxicity. PFS and OS were improved in patients who had received BM in comparison with those potentially eligible but who did not receive BM (P

Published
2017

100. Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials

Author

Grassadonia, Antonino, primary, Sperduti, Isabella, additional, Vici, Patrizia, additional, Iezzi, Laura, additional, Brocco, Davide, additional, Gamucci, Teresa, additional, Pizzuti, Laura, additional, Maugeri-Saccà, Marcello, additional, Marchetti, Paolo, additional, Cognetti, Gaetana, additional, De Tursi, Michele, additional, Natoli, Clara, additional, Barba, Maddalena, additional, and Tinari, Nicola, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results